Cisplatin represents one of the first-line drugs used for non-small-cell lung cancer treatment. However, considerable side effects and the emergence of drug resistance are becoming critical limitations to its application. Combinatorial strategies may be able to extend the use of cisplatin. Both Tanshinone IIA and cisplatin inhibit nonsmall-cell lung cancer cell growth in a time-and dose-dependent manner. When
| INTRODUCTION
The incidence and mortality rate of lung cancer are among the highest for all tumours worldwide (Siegel, Miller, & Jemal, 2017) . Non-smallcell lung cancer (NSCLC) accounts for 85% of all lung cancer cases and can be classified into three subtypes: squamous cell carcinoma, large cell carcinoma, and adenocarcinoma (Webb & Simon, 2010) .
Platinum-based chemotherapy is an important adjuvant therapeutic strategy for NSCLC patients (Jin et al., 2016) . As the most widely used platinum compound, cisplatin (DDP; Figure 1a ) is the first-line chemotherapeutic agent for the treatment of NSCLC and can induce cancer cell cycle arrest and apoptotic cell death (Galluzzi et al., 2014) . However, the tremendous side effects caused by chemotherapy and the development of chemoresistance severely impact the efficacy of treatments as well as quality of life, which accounts for the major chemotherapy failure in both resectable and advanced NSCLC (Wohlkoenig et al., 2011) , indicating that there is room for improvement in treatment methods. Thus, increasing attention has been focused on traditional Chinese medicine (TCM) to explore new cancer approaches that are promising and effective for patients with NSCLC.
TCM, comprises mainly natural products, has recently attracted increasing public attention, and many researchers have explored novel therapeutic targets against NSCLC. Tanshione IIA (Tan IIA; Figure 1b) represents one of the primary fat-soluble compositions that was isolated from Salvia miltiorrhiza, and it is referred to as "Dan-Shen" in TCM. The compound ID of Tan IIA in PubChem compound is 164676.
Tan IIA is prescribed for the treatment of cardiovascular disease in the pharmacopoeia of the People's Republic of China as the TCM "Danshen." Tan IIA has been shown to exhibit antiangiogenic (Tsai, Yang, Wu, Pang, & Huang, 2011) , antioxidant , antiinflammatory, immunomodulatory (Chen & Xu, 2014) , and antitumor activities. A number of studies have shown that Tan IIA antagonizes the proliferation of multiple human cancer cell lines, such as human colorectal cancer (He & Gu, 2018; Sui et al., 2017) , human gastric carcinoma (Su, 2018; Zhang et al., 2018) , human pancreatic cancer (Chiu & Su, 2017) , human breast cancer and (Li & Lai, 2017; Lv et al., 2018) , and human osteosarcoma cells . However, the specific mechanisms of action underlying the anticancer effects of Tan IIA in NSCLC cells remain elusive.
In the present study, the cytotoxic effects of Tan IIA and DDP on NSCLC cells were examined using the Cell Counting Kit-8 assay. The wound healing assay, transwell assay, cell cycle analysis, apoptosis assay, mouse xenograft model, bioinformatics analysis, and western blotting were carried out to investigate and confirm the mechanism of action in A549 and PC9 cells following Tan IIA, DDP, and combination treatment. The data in this study provide many theoretical bases to understand the molecular mechanisms of the cytotoxic effects of the was dissolved in dimethyl sulfoxide to make a 1-mM stock solution and stored at −20°C for future use. DDP was dissolved in physiological saline to make a 10-mM stock solution and stored at −20°C for future use; 740 Y-P was purchased from Beyotime Institute of Biotechnology and dissolved in physiological saline to make a 10-mM stock solution and stored at −20°C for future use.
| Cell viability assay
The antiproliferative effects of Tan IIA and DDP on NSCLC cell lines were detected using the CCK-8 kit (Dojindo Laboratories, 119 Kumamoto, Japan). A549, PC9, H1299, and SPA-A1 cells (8.0 × 10 3 cells each well) were seeded into 96-well plates. The cells were concurrently cultured with various concentrations of Tan IIA and DDP individually and concurrently. After treatment for 24, 48, or 72 hr, the cells were incubated for an additional 90 min with 10 μl of CCK-8 solution. Finally, the optical density was measured at 450 nm using a microculture plate reader (Thermo Scientific, Rockford, IL, USA). The proliferative inhibition rate was calculated using the following formula: proliferative inhibition rate = (1 − experimental group/control group) × 100%. The 50% inhibitory concentration (IC 50 ) value was calculated by non-linear regression analysis using SPSS 20.0 software.
| Synergy determination
The combination index (CI) was determined by isobologram analysis for the combination study, which was based on the Chou-Talalay method. The data obtained from the cell viability assay were standardized to the control group and presented as the % viability. Furthermore, the data were converted to the fraction affected (Fa; range 0-1; where Fa = 0 represents 100% viability and Fa = 1 represents 0% viability) and analysed using the CompuSyn™ programme (Biosoft, Ferguson, MO) based on the Chou-Talalay method. The CI values represent the modes of interaction between the two drugs.
The CI < 1 indicates synergism, CI = 1 indicates an additive effect, and CI > 1 indicates antagonism.
| Wound healing assay
A549 and PC9 cells (1 × 10 6 /1 ml/well) in logarithmic phase were plated into six-well plates. After 24 hr, the adhesive cells were scratched along a straight line using a 200-μl pipette tip and then the scraped cells and cell debris were cleared three times with phosphate buffered saline (PBS). Fresh serum-free medium including various drugs was added to six-well plates, and the cells were allowed to repair the scratches for 24 hr. Images (magnification, ×10) were obtained at 0 and 24 hr at the same place that had been scratched.
Then, Adobe Photoshop CS6 software was applied to measure the moving distance of cells.
| Transwell assay
The transwell filters (8-μm pore, 6.5-mm polycarbonate, Corning, NY, USA) were coated with a thin layer of Matrigel Basement Membrane Matrix (BD Biosciences, Bedford, MA). A549 and PC9 cells (3 × 10 4 ) in logarithmic phase were resuspended in 500-μl serum-free medium containing different drug treatments and plated on the upper compartment, and 800-μl complete medium including 10% FBS was added to the lower compartment. The transwell filters were placed in a humidified incubator at 37°C with 5% CO 2 for 24 hr. Next, the cells attached to the lower surface of the membrane were fixed with 4% paraformaldehyde at room temperature for 30 min and stained with 0.5% crystal violet. The cells on the upper surface of the filter were removed by wiping with a cotton swab. The number of stained cells on the lower surface was then counted using a microscope (magnification, ×100). Five fields were counted for each transwell filter.
| Cell cycle analysis
The Cell Cycle Detection Kit purchased from 4A Biotech Co., Ltd. was used to determine the cell cycle. A549 and PC9 cells (5.0 × 10 5 /1 ml/ well) in logarithmic phase were plated into six-well plates with complete medium containing different drug treatments in a humidified incubator at 37°C with 5% CO 2 for 48 hr. The treated cells were collected and then washed with cold PBS. Subsequently, 70% cold ethanol was applied to immobilize the harvested cells at 4°C overnight.
The cells were washed again with cold PBS and incubated with 100-μl RNase in a 37°C water bath for 30 min, followed by labelling with 400-μl propidium iodide and incubation for 30 min at room temperature in the dark. For each detection, at least 50,000 cells were evaluated. An ACEC NovoCyte flow cytometer equipped with Novoexpress (Becton Dickinson, San Jose, CA, USA) was used to detect the cell cycle.
| Apoptosis assay
The Annexin V-FITC apoptosis detection kit purchased from 4A Biotech Co., Ltd. was applied to detect cell apoptosis. A549 and PC9 cells (5.0 × 10 5 /1 ml/well) in logarithmic phase were plated in six-well plates and treated with different drugs for 48 hr. The treated cells were collected and washed with cold PBS after treatment. In accordance with the manufacturer's instructions, the cells were stained with Annexin V-FITC and propidium iodide for 30 min at room temperature in the dark, and the apoptosis rate of the treated cells was determined immediately after staining by using an ACEC NovoCyte flow cytometer equipped with Novoexpress (Becton Dickinson, San Jose, CA, USA). After washing again with TBST, the immunoreactivity of the membranes was detected using Bio-Rad-Image-Lab with an electrochemiluminescence system (Thermo Fisher Scientific, MA, USA). The densitometry of the protein bands were measured using the Image J (NIH image software) and normalized to their relevant controls.
| Mouse xenograft model

| Statistical analysis
All experiments were repeated at least three times. Data are shown as the mean ± SD and were analysed using GraphPad Prism 6.02 software (San Diego, CA, USA), excluding the IC 50 values that were calculated using SPSS 20.0 software. Differences between groups were analysed using Student's t test. A p value of .05 or less was considered significant. Table 1 .
| Cotreatment of Tan IIA and DDP synergistically inhibited the migration and invasion of NSCLC cells
To identify the combination of Tan IIA and DDP that achieved maximal biological function, we utilized the wound healing assay and transwell assay to study migration and invasion ability of A549 and PC9 cells. Figure 3 demonstrates that both the migration distances and invasive cell numbers were significantly decreased following 24 hr of drug treatment. In addition, the combination treatment exhibited the smallest migration distance and invasive cell number. 
|
| Cotreatment of Tan IIA and DDP synergistically inhibited A549 cell xenograft tumour growth
We next studied the effect of Tan IIA and DDP on xenograft ESCC tumour growth. The experimental set-up, including A549 cell inoculation and drug treatment, is depicted in Figure 6 . In the control group, xenograft tumours were observed to grow faster with a significantly greater tumour volume compared with the group that was treated with the tested drugs. In comparison to the Tan IIA and DDP monotherapy groups, the combined therapy using Tan IIA and 
| Potential target proteins of Tan IIA and the KEGG pathway analysis
Using PharmaMapper, we obtained the Top 300 potential protein target information for Tan IIA (Table S1) , and then the KEGG pathway analysis reminded us that Tan IIA might mainly influence the PI3K-Akt signalling pathway, as shown in Figure 7 . We also utilized molecular docking to study the potential interactions between the tested drugs and PI3K/Akt signalling pathway. Molecular docking analysis demonstrated that both Tan IIA and DDP could be docked into the active site of PI3K, Akt, Caspase-3, and Bcl-2 in the binding pocket.
Tan IIA and DDP were shown to form H-bonds or π-π interactions via different residues with PI3K, Akt, Caspase-3, and Bcl-2 in 10 random poses. Our previous studies have also provided evidence of some natural agents with potential antitumour activity in combination with other therapeutic drug, such as Tan IIA (Xie et al., 2016) and matrine . However, there is no evidence at the cellular level or from animal models demonstrating such an effect of the combination of Tan IIA with DDP on NSCLC progression. The study presented herein indicates that the combination of Tan IIA with DDP diminishes It has been reported that Tan IIA inhibits the migration and invasion ability of bladder cancer cells (Huang, Chang, Liao, & Chiu, 2017) and Tan IIA combined with adriamycin inhibits migration and invasion ability in NSCLC (Xie et al., 2016) . Our findings also showed that Tan IIA combined with DDP could inhibit the migration and invasion ability of A549 and PC9 cells in a synergistic manner.
|
The current study also provides insight into the mechanism of the synergistic effect of Tan IIA in combination with DDP on the cell cycle distribution through the use FCM experiments in A549 and PC9 cells.
FCM showed that both drug combination treatment and single DDP treatment caused S and G2 phase arrest in A549 and PC9 cells, whereas single Tan IIA treatment caused G1 phase arrest. Ma found that in the NSCLC cell line H1299, the proportion of cells in G1 phase was increased compared with the control following treatment with Tan IIA (4 μM, 48 hr; Ma et al., 2015) . However, the effect of Tan IIA on the cell cycle distribution is still controversial. Different results were found using the renal cancer cell line 786-O, for which the percentage of cells in S phase was increased in a dose-dependent manner response to Tan IIA treatment (0, 6.79, 13.59, or 27.18 μM, 24 hr; Wei, Zhou, Hu, & Huang, 2012) . These findings showed that low dosage Tan IIA might contribute to the cell cycle arrest at G1 phase, whereas high dosage Tan IIA might lead to S phase cell cycle blockage, which remains to be further explored.
Many studies have demonstrated that Tan IIA results in an increased apoptosis rate in NSCLC (Chiu & Su, 2010) , and colorectal carcinoma (He & Gu, 2018) . Furthermore, Zhao found that Tan IIA could potentiate the apoptosis rate of DDP in pharyngeal squamous cell carcinoma . Our results also demonstrated that both Tan IIA and DDP were able to produce the same results in A549 and PC9 cells, and compared with single drug treatment, combined application of these two drugs can significantly increase the apoptosis rates. Taken together, these results suggest that the combination treatment of both Tan IIA and DDP could function to synergistically promote apoptosis.
Huang and his team found that Tan IIA induces intrinsic apoptosis in osteosarcoma cells both in vivo and in vitro . Our results also showed that both Tan IIA and DDP could inhibit NSCLC xenograft tumour growth, and the combination of these two exerted more significant effects in vivo. Therefore, our results indicated that Tan IIA could function to effectively increase the antitumour effect of DDP in vivo.
Next, using PharmMapper , we obtained the Top 300 potential protein target information for Tan IIA, and the KEGG pathway analysis reminded us that Tan IIA might mainly influence the PI3K/Akt signalling pathway, which is consistent with some recent studies (Cao, Wang, Li, Zhang, & Qiao, 2018; Chen, 2015; Ding et al., 2017) . Additionally, Su also reported that Tan IIA blocked the PI3K/Akt pathway in gastric carcinoma AGS cells both in vitro and in vivo (Su, 2018) . Similarly, many recent studies also reported that inactivation of the PI3K/Akt pathway could enhance the chemosensitivity of NSCLC cells to DDP Gong, Cui, Wang, Wang, & Han, 2018; Liu, Xing, & Rong, 2018; Shi, Pu, Zhou, Ning, & Bai, 2017; Xia, Li, Li, Lu, & Wu, 2018; Zhao et al., 2018) . Therefore, we conjectured that Tan IIA might block the PI3K/Akt pathway and then enhance the anticancer ability of DDP in NSCLC.
PI3K activity is stimulated by diverse oncogenes and growth factor receptors, and elevated PI3K signalling is considered a hallmark of cancer (Fruman et al., 2017) . Additionally, Akt is an important downstream effector of oncogenic PI3K signalling and regulates several pathways, including inhibition of apoptosis, stimulation of cell growth, and modulation of cellular metabolism (Fruman et al., 2017 Our western blot results revealed that the drug treatment gave rise to distinctly high expressions levels of cleaved-Caspase-3 and Bax but low expressions levels of Bcl-2, Caspase-3, p-Akt, and p-PI3K proteins, with total Akt and PI3K protein expression remaining nearly the same.
The effects of the drug combination treatment showed a more significant difference compared with the single drug treatment. Thus, we hypothesized that the drug induced pro-apoptotic process was likely associated with the down-regulation of the PI3K/Akt signalling pathway. Bax and cleaved Caspase-3 were up-regulated, suggesting that the mitochondrial apoptotic pathway was also involved in Tan 
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